Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL Oral presentation will highlight further the 48-week IMPACT efficacy and ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual ...

Upon abstract acceptance, all posters must be uploaded and recorded on VoiceThread by January 26, 2026 at 5 p.m. All posters that are narrated on VoiceThread by the deadline will be officially listed ...

With the fall ACS national meeting right around the corner, the time has come to put your poster presentation together. While the abstract was submitted months ago, you were waiting to create the ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced a poster ...

NATICK, Mass. -- The future looked bright at the U.S. Army Research, Development and Engineering Command Soldier Center's 12th Annual Future Workforce Poster Presentation, which was hosted recently by ...

‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, ...

NATICK, Mass. (Aug. 11, 2016) -- The U.S. Army Natick Soldier Research, Development and Engineering Center held its 10th Annual Future Workforce Poster Presentation, showcasing science and technology ...

Title: REL-1017 (esmethadone) Did Not Produce Initial or Cumulative Neurotoxic Effects or Other Evidence of Damage to Cortical Neurons The abstract is available on the meeting website and the poster ...

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) ...

Details of the presentations are as follows: Event: Society for Investigative Dermatology 2026 Annual Meeting Presenter: Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics Session Date and Time: ...